Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Steroids and Control of Severe Asthma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Severe persistent asthma bronchiale with diagnosis according to the criteria of the Global Initiative for Asthma (GINA) executive summary~* Treatment with at least inhaled corticosteroids (ICS) and long acting b agonists (LABA)~* Evidence of inflammatory triggered form of asthma with at least one of the following:~* sensitization to typical aerogenous allergens~* increased Serum IgE levels~* Eosinophilia in peripheral blood~* Proven Eosinophilia in sputum differential (\> 3%) in the previous 2 years~* at least 2 exacerbations of asthma within the previous 24 months leading to unscheduled presentation at a health care provider and/or systemic corticosteroid~* Signed informed consent~* Requirements of the local ethics committee are met~Exclusion Criteria:~* Acute exacerbation of asthma within the last 6 weeks Rtot \> 350% predicted capillary pO2 \< 60mmHG, pCo2 \> 50mmHG near fatal asthma or anaphylaxis in history~* Age ≤ 18 and \> 80 years~* Active smoking or \> 15 pack-years former smoking~* Oral steroid treatment with a prednisolon-equivalent dose exceeding 10 mg per day~* Pregnancy, nursing females~* Female without use of effective contraceptive method~* Treatment with investigational drugs over the past 30 days or during the course of the trial~* Severe and uncontrolled gastroesophageal reflux disease~* Ongoing psychiatric disorder~* Treatment with systemic corticosteroids for any reason other than asthma~* Other active lung diseases~* Medical history of other uncontrolled diseases 3 months prior randomization (e.g. infections, coronary heart diseases and metabolic diseases)~* Any history of malignancy requiring ongoing treatment and/or limiting life-expectancy~* Clinically significant abnormalities in electrocardiogram (ECG) or laboratory exams~* Asthma related to non-steroidal anti-inflammatory drug (NSAID)~* Insulin dependent diabetes mellitus~* Cataract

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).